Ibandronate in the treatment of pediatric osteoporosis

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

“…ibandronate infused every 3 months to 27 patients with OI had an inhibitory eff ect on bone turnover markers. We have previously published reports on the benefi cial effect of once-montly orally administered ibandronate in children and adolescents with osteoporosis, where one to three years treatment increased spinal BMD and resulted in fracture reduction (10)(11). In the current report, our 5 of BMD increase.…”

“…In conclusion, once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI. Ibandronate, as well as other antiresorptive bone drugs, is an off-label drug and should be used only in the context of an established clinical program with specialist consultation (1,2,10,11).…”

“…Ibandronate, an eff ective antiresorptive agent, is widely used in the treatment of postmenopausal and male osteoporosis (4,5). So far, it has been only scarcely used in children with low bone mineral density (BMD) and recurrent fractures (6)(7)(8)(9)(10)(11). We present three patients with OI treated with once monthly oral ibandronate.…”